What's in Nobelpharma's pipeline?

Nobelpharma has 16 drugs in our index: 0 marketed, 0 filed, 10 in Phase 3, 4 in Phase 2, 2 in Phase 1.

Which companies overlap with Nobelpharma's portfolio?

Top competitors by shared drug class: Promius Pharma, LLC, AO GENERIUM, GlaxoSmithKline, Hoffmann-La Roche, Takeda.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/nobelpharma.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Nobelpharma — Portfolio Competitive Intelligence Brief

Nobelpharma pipeline: 0 marketed, 0 filed, 10 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 10 Phase 3 4 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
NPC-16 Continuous Dosing Regimen Group	NPC-16 Continuous Dosing Regimen Group	phase 3	S1P receptor modulator	S1PR1	Immunology
NPC-02	NPC-02	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
NPC-01	NPC-01	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
IKH-01	IKH-01	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
NPC-16 Standard Dosing Regimen Group	NPC-16 Standard Dosing Regimen Group	phase 3	S1P receptor modulator	S1PR1	Immunology
NPC-15	NPC-15	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
NPC-07 for oral administration	NPC-07 for oral administration	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
NPC-09	NPC-09	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
NPC-12Y gel	NPC-12Y gel	phase 3			Dermatology/Wound Care
Norethisterone,Ethinylestradiol	Norethisterone,Ethinylestradiol	phase 3	progestogen-estrogen combination	progesterone receptor, estrogen receptor	Women's Health

Therapeutic area mix

Diabetes · 6
Immunology · 2
Dermatology/Wound Care · 1
Women's Health · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Promius Pharma, LLC · 2 shared drug classes
AO GENERIUM · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
Hoffmann-La Roche · 2 shared drug classes
Takeda · 2 shared drug classes
Teva Branded Pharmaceutical Products R&D, Inc. · 2 shared drug classes
AceLink Therapeutics, Inc. · 1 shared drug class
Abbott · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Nobelpharma:

Cite this brief

Drug Landscape (2026). Nobelpharma — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nobelpharma. Accessed 2026-05-14.